Laryngeal Diseases
Pathological processes involving any part of the LARYNX which coordinates many functions such as voice production, breathing, swallowing, and coughing.
Subtype terms (14)
More specific conditions that are subtypes of Laryngeal Diseases in the MeSH hierarchy.
- Granuloma, Laryngeal
2 drugs approved
- Laryngeal Edema
3 drugs approved
- Laryngeal Neoplasms
61 drugs (39 approved, 22 experimental)
- Laryngeal Nerve Injuries
- Laryngitis
4 drugs (3 approved, 1 experimental)
- Laryngocele
- Laryngomalacia
3 drugs approved
- Laryngopharyngeal Reflux
12 drugs (8 approved, 4 experimental)
- Laryngostenosis
4 drugs (3 approved, 1 experimental)
- Supraglottitis
- Tuberculosis, Laryngeal
- Vocal Cord Dysfunction
17 drugs (12 approved, 5 experimental)
- Vocal Cord Paralysis
4 drugs (2 approved, 2 experimental)
- Voice Disorders
9 drugs (6 approved, 3 experimental)
Drugs by status
Phase 4 trials (3)
Phase 3 trials (3)
Phase 2 trials (1)
Phase 1 trials (1)
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (14)
- TAP Pharmaceuticals
- Sanofi
- National Cancer Institute (NCI)
- Boston University
- Centre Georges Francois Leclerc
- NRG Oncology
- Radboud University
- Radiation Therapy Oncology Group
- Groupe Oncologie Radiotherapie Tete et Cou
- François Rabelais University
- University of Lille
- European Organisation for Research and Treatment of Cancer
- Dutch Cancer Society
- American Laryngological Association
Organization Involved with Phase 2 Indications (22)
- Merck
- University of Pennsylvania
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Case Western Reserve University
- Cornell University
- Danish Head and Neck Cancer Group
- Eastern Cooperative Oncology Group
- Temple University
- University of Washington
- Ohio State University
- Southwest Oncology Group
- University of South Florida
- University of Toronto
- University of Virginia
- University of Leipzig
- University of California, Los Angeles
- University of Chicago
- Medical University of Vienna
- University of Texas at Houston
- State University of New York, Buffalo
- University of Texas, San Antonio
- National Comprehensive Cancer Network
Organization Involved with Phase 1 Indications (9)
Organization Involved with Other Experimental Indications (3)